“Geistlich is very pleased to have StimLabs as an exclusive distribution partner of Derma-Gide in the United States to offer our Advanced Wound Matrix to patients suffering from difficult to heal wounds,” said Diego Gabathuler, CEO of Geistlich. The Derma-Gide wound matrix is now listed in the national healthcare insurance Medicare reimbursement list for the for treatment of diabetic foot ulcers (DFUs). This enables StimLabs to leverage their national channel to support clinicians in the adoption and utilization of this highly differentiated technology.
Derma-Gide Advanced Wound Matrix is an innovative and US-cleared solution made from highly purified porcine collagen. It is indicated for the management of wounds. Its unique design characteristics support wound healing and provide ease of use and handling for health care providers.
StimLabs CEO John Daniel commented on the agreement «We look forward to working with Geistlich, a trusted global leader in regenerative technologies and are pleased to add a high quality, clinically proven xenograft option to our portfolio.»